Irm LLC

Christopher Cow

Robert Epple

Mihai Azimioara

Victor Ivanovich Nikulin

Gerald Lelais

Pierre-Yves Michellys

Songchun Jiang

Phillip B Alper

Pingda Ren

Yun He

Xiaolin Li

Valentina Molteni

Xiaodong Wang

Xing Wang

Yongping Xie

Jon Christopher Loren

Juliet Nabakka

Zuosheng Liu

Xiaodong Liu

Donatella Chianelli

Taebo Sim

Daniel Mutnick

Shuli You

Ross Russo

Lucas Westcott-Baker

John Mecom

Hans Martin Seidel

Phillip Alper

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

Compounds and compositions as modulators of GPR119 activity

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120.

Compounds and methods for modulating G protein-coupled receptors

The invention provides compounds of Formula I: wherein A, L, m, q, Q, R, R, R, Rand Rare defined in the Summary of the Invention. The invention further provides for pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

The invention provides trisubstituted pyrazoles and imidazoles of Formula I: wherein L, q, R, R, R, R, Zand Zare as described in the Summary of the Invention; and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the peroxisome proliferator-activated receptor (PPAR) families, particularly the activity of PPAR&#x3b4;.

Compounds and compositions as PPAR modulators

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR&#x3b1;, PDGFR&#x3b2;, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2&#x3b2;, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Compositions and methods for modulating c-kit and PDGFR receptors

Growing community of inventors

San Diego, CA, United States of America

Christopher Cow